Biotest (BIO) AI Stock Analysis

• Market Cap: €1.37B
• Dividend Yield: 0.1%
• Average Volume (3M): 52.00
• Price to Earnings (P/E): 64.1
• Beta (1Y): -0.06
• Revenue Growth: -18.82%
• EPS Growth: -113.85%
• Country: DE
• Employees: 2,495
• Sector: Healthcare
• Sector Strength: 42
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 19,785,727
• 10 Day Avg. Volume: 99
• 30 Day Avg. Volume: 52
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €44.00
• Price Target Upside: 12.82% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: €39.00 ▲(0.00%Upside)

Biotest's overall stock score is driven by mixed financial performance with strengths in balance sheet stability and cash flow improvements, but offset by operational inefficiencies and inconsistent profitability. Technical analysis indicates bearish momentum, while valuation metrics raise concerns due to a negative P/E ratio, despite a high dividend yield.

Biotest Business Overview & Revenue Model

Company Description

Biotest (BIO) is a global biopharmaceutical company that specializes in the development, production, and marketing of plasma protein products and biological drugs. Operating in the healthcare and biotechnology sectors, Biotest offers a range of products primarily aimed at treating blood disorders, immune system deficiencies, and other critical health conditions. The company's core product portfolio includes immunoglobulins, coagulation factors, and albumins, which are vital for patients with rare and chronic diseases.

How the Company Makes Money

Biotest makes money through the sale of its plasma protein products and biological drugs. The company's revenue model is largely based on the collection of human plasma, which is then processed into a variety of therapeutic products. These products are distributed and sold to hospitals, healthcare providers, and pharmaceutical companies worldwide. Key revenue streams include the sales of immunoglobulins for immune deficiencies, coagulation factors for hemophilia, and albumins for volume replacement therapies. Additionally, Biotest may engage in strategic partnerships and collaborations with other pharmaceutical companies to enhance its product offerings and expand its market reach, further contributing to its earnings.

Biotest Financial Statement Overview

Summary

Biotest shows balanced financial performance with a stable balance sheet and improved cash flows. However, there are challenges in maintaining consistent profitability due to operational inefficiencies.

Income Statement

Biotest's income statement shows a mixed performance. Gross Profit Margin improved to 30.82% in the latest year, coupled with a positive Net Profit Margin of 3.63%, indicating moderate profitability. However, the company experienced a significant drop in Gross Profit from the previous year, suggesting volatility in profit generation. Revenue growth from 2023 to 2024 was 6.08%, which is positive but marked by a decline in EBIT and EBITDA margins, indicating rising operational costs or inefficiencies.

Balance Sheet

The balance sheet of Biotest indicates a stable financial position. The Debt-to-Equity Ratio stands at 1.13, reflecting a balanced capital structure. Return on Equity is modest at 4.97%, showing moderate returns to equity holders. The Equity Ratio of 37.00% suggests a strong equity base relative to total assets, enhancing financial stability. However, the increase in total debt over time could pose potential risks if not managed well.

Cash Flow

Biotest's cash flow statements reveal stable cash flow management. Operating Cash Flow to Net Income Ratio is 2.31, indicating strong cash generation relative to net income. Free Cash Flow improved significantly to a positive $32.2 million in 2024 from a negative position in the prior year, suggesting robust cash flow improvement. However, the fluctuation in free cash flow growth over the years denotes potential instability in cash generation capability.

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Biotest Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 39.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:BIO, the sentiment is Negative. The current price of 39 is below the 20-day moving average (MA) of 41.61, below the 50-day MA of 41.78, and below the 200-day MA of 41.63, indicating a bearish trend. The MACD of -0.34 indicates Positive momentum. The RSI at 41.50 is Neutral, neither overbought nor oversold. The STOCH value of 22.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:BIO.

Biotest Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EUZ	78 Outperform	€1.35B	39.27	17.48%	0.75%	15.89%	14.62%
ILM1	76 Outperform	$313.21M	20.82	2.99%	―	5.62%	-21.87%
Sector *	65 Neutral	€6.45B	18.49	-1.30%	2.20%	-0.15%	-41.32%
FYB	62 Neutral	€535.23M	5.89	-26.06%	―	-10.32%	-250.76%
BIO	51 Neutral	€1.37B	64.15	-4.72%	0.10%	-18.82%	-113.85%
EVT	46 Neutral	€1.32B	―	-20.51%	―	1.50%	-127.76%